Syndicate Investing: How to Collaborate with Other Investors for Better Deals
Executive Summary / Key Results
When entrepreneur Sarah Chen pitched her health-tech startup, MediConnect, on our show, she wasn’t just looking for money—she was looking for a coalition of investors who could provide strategic guidance and industry connections. What followed was a textbook example of syndicate investing in action. The results speak for themselves:
| Metric | Result |
|---|---|
| Total funding raised | $2.5 million within 6 months |
| Number of investors in syndicate | 12 angel investors, including 2 from the show |
| Revenue growth (first year post-investment) | 340% |
| Valuation increase | 5x (from $3M to $15M) |
| Time to close | 8 weeks (industry average: 4-6 months) |
This case study demonstrates how angel syndicates and co-investing strategies can unlock better deals for both investors and entrepreneurs.
Background / Challenge
MediConnect aimed to streamline telemedicine for rural hospitals. The company had a working prototype and early traction with two pilot hospitals, but lacked the capital to scale. Traditional venture capital firms were hesitant due to the perceived risk in healthcare, and individual angel investors lacked the capacity to write a $500,000 check.
The syndicate lead, John Sterling—a seasoned investor and former healthcare executive—identified a critical need: to pool resources and expertise through a structured syndicate. The challenge was to coordinate multiple investors with varying risk appetites, negotiate terms collectively, and ensure streamlined decision-making.
Additionally, MediConnect’s founder was a first-time entrepreneur, making it essential for the syndicate to provide mentorship and operational support. As discussed in [The Investor’s Playbook: How to Evaluate Founders During Pitch Meetings](/post/the-investor-s-playbook-how-to- evaluate-founders-during-pitch-meetings), evaluating founder readiness is a key step in syndicate success.
Solution / Approach
The syndicate adopted a co-investing strategy with a clear framework:
- Lead Investor Role: John Sterling negotiated a standard deal structure on behalf of the group, setting a pre-money valuation of $3M and a convertible note with a 20% discount.
- Pro Rata Rights: Each investor committed a minimum of $50,000, with the option to increase their stake in future rounds.
- Governance: A single Special Purpose Vehicle (SPV) was created to hold all syndicate shares, simplifying legal and reporting obligations.
- Due Diligence: The syndicate pooled expertise—two former hospital administrators assessed product-market fit, while a tech lead evaluated the codebase.
This approach mirrors best practices in syndicate investing, where angel syndicates amplify deal flow and reduce risk through diversification.
Implementation
The implementation unfolded in three phases:
Phase 1: Deal Sourcing and Screening (Weeks 1-2)
MediConnect was vetted through our platform’s screening process. John Sterling attended the pitch, then circulated a deal memo to his network. Within two weeks, 12 investors expressed interest.
Phase 2: Due Diligence and Term Sheet (Weeks 3-5)
The syndicate conducted comprehensive due diligence. They uncovered a competitor’s patent that could block MediConnect’s core algorithm, and negotiated a licensing agreement before closing. This collaborative risk mitigation is a hallmark of effective co-investing strategies.
Phase 3: Closing and Post-Investment (Weeks 6-8)
The syndicate closed the round—$2.5M from 12 investors—in just 8 weeks, compared to the typical 6 months. Post-investment, three syndicate members joined the advisory board, providing introductions to hospital networks and regulatory experts.
Results with Specific Metrics
The syndicate’s collaborative model delivered outsized returns:
| Metric | Pre-Investment | Post-Investment (18 months) |
|---|---|---|
| Monthly recurring revenue | $15,000 | $210,000 |
| Number of hospital contracts | 2 | 18 |
| Patient users | 500 | 25,000 |
| Team size | 5 employees | 35 employees |
| Valuation | $3,000,000 | $15,000,000 |
For the syndicate, each investor’s initial $50,000 stake (on average) is now valued at $250,000. Two investors have already exited partially through secondary sales, realizing a 4x return in 18 months.
Key Takeaways
- Syndicate investing enables larger, smarter bets: By pooling capital and expertise, investors can back companies like MediConnect that are too large for individual angels but too early for institutional VCs.
- Structure matters: A clear lead investor and SPV streamline negotiations and reduce friction.
- Collaborative due diligence is a competitive advantage: As this case shows, syndicates can spot and solve problems that individual investors might miss.
- Relatable founder evaluation is critical: For more on assessing entrepreneurs, see The Investor’s Playbook: How to Evaluate Founders During Pitch Meetings.
About Our Show
Our show connects entrepreneurs with top investors nationwide. Each episode features pitches from startups seeking funding and mentorship. Since 2015, we have facilitated over $100 million in investments, spanning industries from healthcare to clean energy. Our platform is where deal flow meets expert capital.
For investors interested in joining future syndicates, subscribe to our newsletter for deal alerts. Whether you are new to syndicate investing or an experienced angel, our community offers the tools and connections to co-invest with confidence.
